Table 3.
Antibody responses in patients vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1
|
100 μg |
200 μg |
||||||
|---|---|---|---|---|---|---|---|
| pt No. | Vaccination cycle | Baseline (dilution titer) | Antibody response (cycle*) | pt No. | Vaccination cycle | Baseline (dilution titer) | Antibody response (cycle*) |
| 100-01 |
9 |
negative |
responded(4) |
200-01 |
15 |
negative |
responded(2) |
| 100-02 |
3 |
negative |
no response** |
200-02 |
9 |
negative |
responded(2) |
| 100-03 |
3 |
negative |
no response** |
200-03 |
8 |
positive (x1,600) |
responded(5) |
| 100-04 |
7 |
negative |
no response |
200-04 |
21 |
negative |
responded(2) |
| 100-05 |
2 |
negative |
no response |
200-05 |
3 |
negative |
responded(2) |
| 100-06 |
16 |
positive (x6,400) |
responded(1) |
200-06 |
10 |
positive (x400) |
responded(1) |
| 100-07 |
9 |
positive (x25,600) |
no response |
200-07 |
3 |
positive (x25,600) |
responded(2)** |
| 100-08 |
10 |
negative |
responded(1) |
200-08 |
11 |
positive (x400) |
responded(1) |
| 100-09 |
5 |
negative |
no response |
200-09 |
18 |
positive (x400) |
responded(3) |
| 100-10 |
27 |
positive (x400) |
responded(3) |
200-10 |
11 |
positive (x400) |
responded(2) |
| 100-11 |
8 |
negative |
responded(2) |
200-11 |
3 |
positive (x400) |
responded(2) |
| 100-12 |
8 |
negative |
responded(2) |
200-12 |
9 |
negative |
responded(1) |
| 100-13 |
26 |
negative |
responded(2) |
|
|
|
|
| antibody response rate | 53.8%*** | 100%*** | |||||
*vaccine cycles with which antibody responses appeared. **antibody responses assayed after two vaccinations.***p = 0.015(Fisher’s exact test).